TWST

Twist Bioscience Corp

Ticker: TWSTHealthcareBiological Products
HQ SOUTH SAN FRANCISCO, CACIK 1581280FY end 09-30Book / share $7.22Shares 62M
Revenue (FY)
$376.57M+20.32%
TTM $431.80M
Op. margin
-36.18%+34.37%
TTM -33.58%
Net income
$-77.67M+62.79%
TTM $-136.72M
Operating cash
$-47.63M+25.69%
TTM $-53.07M
Free cash flow
$-75.63M-9.34%
TTM $-98.12M
Return on equity
-16.42%+18.25%
TTM -30.67%
Debt / equity
0.03
TTM 0.03
Shares outstanding
59.8M+3.09%
TTM 61.7M

The business

Twist Bioscience Corporation (NASDAQ: TWST) operates as a leading provider of synthetic DNA and related life sciences solutions, serving customers across research, development, and commercial applications globally. The company's website is www.twistbioscience.com.

The company has developed a disruptive DNA synthesis platform that industrializes the engineering of biology through proprietary silicon-chip-based technology. Rather than using traditional plate-based synthesis methods, Twist manufactures synthetic DNA by writing over one million oligonucleotide pieces directly onto silicon chips approximately the size of a large mobile phone, reducing chemical usage by an estimated 99.8% compared to conventional approaches. This core platform combines silicon-based DNA writing technology with proprietary software, scalable commercial infrastructure, and an e-commerce platform to deliver high-quality, precise, and cost-effective DNA synthesis at significant manufacturing throughput.

Twist generates revenue through two primary product lines and a services offering. The synthetic biology segment includes synthetic genes, gene fragments, oligonucleotide pools, IgG proteins, and synthetic controls. The next-generation sequencing tools segment provides library preparation kits, exome kits, fixed and custom panels, and workflow solutions for diagnostic applications. The company also offers comprehensive biopharma services for antibody discovery, optimization, and development, including in vivo, in vitro, and in silico discovery platforms. In fiscal year 2025, the company reported revenue of $376.6 million, with healthcare representing $215.1 million, chemicals and materials $93.2 million, academic research $65.9 million, and food and agriculture $2.4 million.

The company serves more than 3,800 customers across academic institutions, biopharmaceutical companies, diagnostic firms, and industrial biotechnology organizations. As of September 30, 2025, Twist employed 979 people across its operations, including 412 in manufacturing and operations, 278 in sales and marketing, 198 in general and administrative functions, and 91 in research and development. The company operates manufacturing facilities in South San Francisco, California and Wilsonville, Oregon, and maintains a global commercial presence through direct sales personnel, e-commerce platforms, and commercial consultants in Europe and Asia.

Sector
Healthcare
Industry
Biological Products
HQ
SOUTH SAN FRANCISCO, CA
FY end
09-30
CIK
1581280
SIC
2836
Financial performance · annual
20192025
$-282.83M$-87.93M$106.97M$301.87M$496.76M2019202020212022202320242025TTMTTMTTM

Ownership

Who holds Twist Bioscience Corp — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30

330
funds hold it
1 of 35
superinvestors hold it
$2.86B
fund-held value
54.2%
of shares held by funds

Top fund holders

Fund% of fundValue
ARK Innovation ETF
ARKK · ARK ETF Trust
3.05%$197.72M
VANGUARD TOTAL STOCK MARKET INDEX FUND
VTI · VANGUARD INDEX FUNDS
0.01%$192.85M
iShares Russell 2000 ETF
IWM · iShares Trust
0.20%$163.99M
State Street(R) SPDR(R) S&P(R) Biotech ETF
XBI · SPDR SERIES TRUST
1.41%$151.14M
VANGUARD SMALL-CAP INDEX FUND
VB · VANGUARD INDEX FUNDS
0.07%$139.63M

Superinvestors in Twist Bioscience Corp

Polen CapitalINCREASED +130.1%
Polen Capital Management
<0.1%

Share of each manager's reported 13F portfolio.

Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.

Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.

Go deeper in your own AI

15 years of statements, narrative and filings — queryable over MCP.

Read TWST's last four 10-Qs: what changed in segment trends, margins and management's narrative?
Run in your AI →

Professionals can also use the built-in AI chat (subscription + your own Anthropic key).

15 years of Twist Bioscience Corp's financials

Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.

Sign in free